Login / Signup

SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer.

Massimo RuggeManuel ZorziStefano Guzzinati
Published in: Nature cancer (2020)
In 84,246 consecutive Italians tested for SARS-CoV-2, we examined the prevalence of cancer and clinical outcomes of viral infection. Overall, 5.7% (4,789/84,246) had previously been diagnosed with cancer and, among the SARS-CoV-2-positive (CV2+ve) patients, 7.8% had a cancer diagnosis (723/9,275). Prevalence of cancer was not associated with risk of infection (odds ratio of 0.97; 95% confidence interval of 0.89-1.06). The proportion of CV2+ve people hospitalized was higher among patients with cancer (56.6 versus 34.4% among other people), and so was the proportion of deaths (14.7% versus 4.5%). The risk of adverse outcomes of SARS-CoV-2 infection was significantly higher for patients with cancer versus those without, particularly for males and older people.
Keyphrases
  • sars cov
  • papillary thyroid
  • squamous cell
  • respiratory syndrome coronavirus
  • end stage renal disease
  • risk factors
  • lymph node metastasis
  • newly diagnosed
  • chronic kidney disease
  • ejection fraction